SCHEMBL5701158

SCHEMBL5701158

c1ccc2cc(OCCCNC3CCCCC3)ccc2c1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.61
ALDH1A1 P00352 5/20 0.59
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C19 P33261 1/20 0.55
XDH P47989 1/20 0.52
HRH3 Q9Y5N1 4/20 0.50
PPARG P37231 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
FAAH O00519 1/20 0.50
EPHX1 P07099 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5701136 0.96 KDM4E (0.56) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL5701229 0.96 KDM4E (0.60) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL23074698 0.83 ALDH1A1 (0.70) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL12204135 0.83 ALDH1A1 (0.70) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL12204176 0.79 KDM4E (0.77) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL12204181 0.79 XDH (0.60) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL12204322 0.79 KDM4E (0.56) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL2352175 0.79 KDM4E (0.69) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL12204238 0.78 KDM4E (0.70) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
Hydrochloric Acid SCHEMBL11620192 0.77 ALDH1A1 (0.59) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7081465-B2 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-25 US claimed
EP-1682484-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-26 EP disclosed
US-7081465-B2 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-25 US disclosed
WO-2005042465-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-05-12 WO disclosed
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders APOB, LIPC, FABP3 KDM4E 2830/4885ALDH1A1 717/4885KMT2A 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.